INTRODUCTION {#S5}
============

Transabdominal rectal resection following the principles of total mesorectal excision (TME) has been the mainstay treatment for patients with localized rectal cancer for decades.^[@R1]^ While effective in providing local tumour control, TME is associated with significant morbidity and long-lasting consequences. These include sexual and urinary dysfunction, significant defecatory problems, or a permanent stoma.^[@R2]-[@R4]^ Consequently, many patients experience a significant decline in quality of life QOL after TME. Alternatives to TME that are capable of achieving the same cure rate, while preserving function, would improve patients' QOL significantly.

The need for TME in patients with tumours localized to the bowel wall, which have not spread to the mesorectal lymph nodes, has long been questioned.^[@R5]^ Local excision (LE) has been proposed as an alternative for these patients. However, LE in early-stage cancer is associated with higher local recurrence (LR) rates than TME.^[@R6]-[@R8]^ Furthermore, while patients who develop LR after LE can theoretically undergo salvage TME, many have incomplete resections, with recurrence extending beyond the tissues removed by standard TME.^[@R9]-[@R11]^ Survival after LE is therefore inferior compared to TME, particularly in patients with T2N0 tumours.^[@R12]-[@R14]^

A number of studies have proven that radiotherapy (RT) or chemoradiotherapy (CRT) before TME is associated with a lower rate of LR, compared to either TME alone, or TME followed by CRT. Based on these studies, neoadjuvant CRT (nCRT) followed by TME has become the standard treatment for patients with locally advanced rectal cancer (LARC).^[@R15],\ [@R16]^ The benefits of nCRT in LARC patients treated with TME have hastened interest in use of nCRT before LE for early-stage rectal cancer. Several retrospective case series, and a single-institution prospective study, have suggested that nCRT before LE may result in local tumour control comparable to that of TME for tumours of similar stage.^[@R17]-[@R20]^ However, these studies are limited by small size, variable clinical staging criteria, heterogeneous tumour characteristics, and varying nCRT regimens. Prospective data from larger multi-center trials are needed.

The American College of Surgeons Oncology Group (ACOSOG) designed a prospective multi-institutional, phase 2 trial to investigate the feasibility of using nCRT before LE to achieve organ preservation in patients with endorectal ultrasound (ERUS)- or endorectal coil magnetic resonance imaging (EC-MRI)-staged T2N0 rectal cancer located within 8 cm of the anal verge. Select secondary endpoints of this trial have already been reported.^[@R21]^ Given more mature follow-up on all patients enrolled, we now report the primary endpoints of tumour recurrence and survival at 3 years, and anorectal function and QOL at 1 year.

METHODS {#S6}
=======

Study Design and Participants {#S7}
-----------------------------

The study design has been reported previously.^[@R21]^ This was a phase 2, single arm, non-randomized, open-label trial conducted at American College Of Surgeons Oncology Group Institutions. Patients with clinical T2N0 rectal adenocarcinoma staged by ERUS or EC-MRI, measuring \< 4 cm in greatest diameter, involving \< 40% of the circumference of the rectum, and located within 8 cm of the anal verge, were included. All patients underwent complete colonoscopy, rigid proctoscopy, digital rectal exam (DRE), abdominal and pelvic CT, and chest x-ray or chest CT. All had Eastern Cooperative Oncology Group Performance Score (ECOG PS) of ≤ 2. Patients with tumours fixed to adjacent structures on DRE were ineligible. The protocol schema is shown in [Figure 1](#F1){ref-type="fig"}. The study was approved by the Institutional Review Boards at all participating institutions. Data was submitted to the ACOSOG statistical center.

Procedures {#S8}
----------

External beam RT with megavoltage linear accelerators (≥ 6 MV) was delivered to a 3-4 field pelvis arrangement, following CT-based simulation and computer-assisted treatment planning. Intensity-modulated RT (IMRT) was allowed (IMRT guidelines available at:<http://www.acosog.org>). The original dose (OD) of RT consisted of 1.8 Gy/day 5 days/week for 5 weeks to a dose of 45 Gy to PTV1, then a boost to PTV2 (defined as GTV plus 2cm) for a total dose of 54 Gy. This was accompanied by capecitabine (825mg/m^2^, twice daily, on days 1-14 and 22-35) and oxaliplatin (50mg/m^2^ weeks 1, 2, 4, 5). The OD of nCRT was found to have unfavorable toxicities; this led to a revised dose (RD) regimen after 53 patients had been accrued. The RT was reduced to a total of 50.4 Gy, and capecitabine was reduced to 725 mg /m^2^, twice daily, 5 days/week, for 5 weeks. The dose of oxaliplatin was not changed. Surgery was performed 4-8 weeks after completion of nCRT. LE was done using conventional transanal excision (TAE) or transanal endoscopic microsurgery (TEM). Full-thickness excision of the tumour with a 1 cm surrounding margin of normal rectal wall was required. All participating surgeons had performed at least 3 LEs with negative margins, and completed a skills verification program.

Staging of surgical specimens was performed according to AJCC criteria. Specimens without evidence of dysplastic epithelium or invasive cancer were classified as having pathologic complete response (pCR). Specimens with dysplastic epithelium at the original tumour site, but without evidence of invasion, were staged as ypTis (carcinoma *in situ*), rather than pCR.

Patients received an initial post-operative exam 1 month after surgery. DRE, proctoscopy and ERUS were given every 4 months for 3 years, and every 6 months for the next 2 years. Colonoscopy was required at 3 years. Other tests for LR or distant metastasis (DM) were performed if indicated.

Outcomes {#S9}
--------

The primary endpoint was 3-year disease-free survival (DFS). Evidence of LR, DM, or death from any cause within 3 years counted as events in the time-to-event Kaplan-Meier analysis^[@R22]^ of DFS. All protocol-eligible patients were considered on an intent-to-treat analysis. Per-protocol analyses were also performed, for which patients were considered evaluable if they underwent nCRT and LE and had ypT0, ypT1, or ypT2 tumours with negative margins.

Secondary endpoints were the proportion of patients having negative resection margins after LR, the proportion of patients with a pCR, the procedure-specific morbidity and mortality following nCRT and LE, and the impact of nCRT followed by LE on anorectal function and QOL.

Anorectal function and QOL were evaluated at the time of enrollment and 12 months after surgery using the Fecal Incontinence Severity Index (FISI)^[@R25]^ and the Functional Assessment of Cancer Therapy-Colorectal (FACT-C)^[@R26]^ questionnaires. The FISI addresses varying frequencies of leakage of gas, mucus, liquid or solid stool, with higher scores indicative of worse anorectal function. The FACT-C questionnaire comprises 5 subscales: 4 measuring concerns related to general health -related --QOL, Physical Well-Being (PWB), Social/Family Well Being (SFWB), Emotional Well-Being (EWB), Functional Well-Being (FWB); and 1 subscale measuring concerns related specifically to colorectal cancer - the Colorectal Cancer Subscale (CCS). The FACT-C total score is the sum of all 5 subscales. A higher score represents better QOL and overall function.

Statistical analysis {#S10}
--------------------

The sample size was calculated using the per-protocol patient set. A 3-year DFS probability of \< 0.80 was considered unacceptably low, while a probability of \> 0.91 was considered clinically promising. Assuming a significance level of 0.1, 70 evaluable patients were needed to distinguish a null 3-year DFS event rate of 0.80 from an alternative rate of 0.91 with 90% power. We estimated that up to 5% of patients would not tolerate nCRT, up to 10% would exhibit pathological ypT3 tumours or positive resection margins, and up to 15% would not be evaluable for the primary endpoint; therefore, we targeted a total accrual of 83 patients, to ensure at least 70 evaluable patients for per-protocol analyses. In addition to computation of 3-year DFS, the survival profile of enrolled patients was summarized graphically over 5 years of follow-up using the Kaplan-Meier estimator. Differences between grouped survival profiles were assessed with the Log-rank test^[@R22]^. The Wilcoxon rank-sum test^[@R23]^ and Fisher's exact test^[@R24]^ were used to compare continuous and categorical variables between dose groups. All reported P-values were based on two-sided tests; confidence intervals assumed a significance of 0.05. Anorectal function and QOL at baseline, and 12 months following surgery, were compared using the Wilcoxon Signed Rank test.

The trial is registered with [ClinicalTrials.gov](http://ClinicalTrials.gov), number NCT00114231.

Role of the Funding Source {#S11}
--------------------------

The ACOSOG participated in the study design, data collection, data storage, and data analysis, but had no role in writing the report. Only LAR, QS and XWC had access to the raw data. The corresponding author had access to the analyzed data, not the raw data, but had final responsibility for the decision to submit the manuscript.

RESULTS {#S12}
=======

Seventy-nine eligible patients were accrued to the trial from May 25^th^ 2006 to October 22^nd^ 2009, and began nCRT. They represent the intention-to-treat group ([Table 1](#T1){ref-type="table"}). Patient disposition and analysis groups are presented in [Figure 2](#F2){ref-type="fig"}. Two patients did not have surgery. The pathologic results for all 77 patients undergoing surgery have been previously published.^[@R21]^ Of these 77 patients, 38 (49%) had ypT0 or ypTis tumours; 11 (14%) ypT1 tumours; 24 (31%) ypT2 tumours; 3 (4%) ypT3 tumours; 1 (1%) ypTx tumour. The proportions of all patients experiencing AEs during nCRT and stratified by dose groups are presented in [Table 2](#T2){ref-type="table"}. Surgery-related toxicities are presented in [Table 3](#T4){ref-type="table"}.

In total, 76 patients had nCRT and LE, either TEM (29 patients or 38%) or TAE (47 patients or 62%). One patient had positive resection margins and underwent APR, as required per protocol, with no residual tumour identified in the surgical specimen. The patient died 10 months later from surgery-related complications. Three additional patients had ypT3 tumours, and two of these underwent APR within six weeks of LE. Neither APR specimen revealed cancer; both patients were alive and without evidence of disease at 40 and 47 months from LE, respectively. The third patient refused APR and developed pelvic recurrence. The remaining 72 patients underwent nCRT and LE and had ypT0-2 and negative resection margins, comprising the per-protocol group.

Patients have been followed for a median 56 months (IQR 46-63 months) after surgery, with no treatment-related deaths. Five died from non-cancer-related causes 8-38 months after surgery. At the end of the follow-up period, eight of 79 patients (10%) have developed recurrence: five of 79 (6%) with DM and three of 79 (4%) with LR as initial sites of failure. None have developed both DM and LR. Characteristics of the eight patients with recurrent tumour, salvage treatment received, and tumour and survival status at the end of follow-up are presented in [Table 4](#T5){ref-type="table"}. Two patients with LR underwent salvage APR, with negative margins. One patient whose APR specimen showed tumour limited to the muscularis propria developed further pelvic recurrence, and died of disease 48 months after LE. The second patient had carcinoma *in situ* in the APR specimen, and remains alive and free of disease 48 months after LE. One patient with a ypT3 tumour in the surgical specimen refused TME and developed LR.

The estimated 3-year DFS for the intent-to-treat group was 0.88 (95% CI: 0.81, 0.96), and for the per-protocol group 0.87 (95% CI: 0.79, 0.95) ([Figure 3](#F3){ref-type="fig"}). Three-year OS for the intent-to-treat group was 0.96 (95% CI: 0.90, 1.00), and for the per-protocol group 0.96 (95% CI: 0.91, 1.00) ([Figure 4](#F4){ref-type="fig"}). Five of the recurrences developed in patients receiving the OD, three in patients receiving the RD. The 3-year DFS and OS by OD versus RD groups for the intent-to-treat group are presented in [Supplemental Figure 1](#SD1){ref-type="supplementary-material"}. We found no differences in 3-year DFS or overall survival between patients treated with TEM and TAE ([Supplemental Figure 2](#SD3){ref-type="supplementary-material"}).

At the end of follow-up, 72 (91%) of 79 patients receiving nCRT and LE had rectal preservation. All 72 patients completed the baseline FISI and FACT-C questionnaires, but only 62 (86%) completed them one year after surgery. We found no significant deterioration in the overall FISI scores or any of the subscales one year after surgery, compared to baseline ([Table 5](#T6){ref-type="table"}). We found no difference in the overall FACT-C scores between baseline and one-year evaluations ([Table 5](#T6){ref-type="table"}). However, patients experienced deterioration in the physical well-being subscale, and an improvement in the emotional well-being subscales ([Table 5](#T6){ref-type="table"}).

DISCUSSION {#S13}
==========

The results of this multi-institutional prospective trial indicate that the vast majority of patients with clinically staged T2N0 rectal cancer treated with nCRT and LE preserved the rectum. The LR rate for all patients was 4%, and the estimated 3-year DFS for the intention-to-treat group and for the per-protocol groups were within the margin of efficacy defined in the study design. However, the lower limit of the 95% confidence interval of 3-years DFS for the per-protocol group, the one used for the sample size calculation, reached the threshold for considering it unacceptably low. Thus, while the results are encouraging, the study did not achieve its goal using the strictly pre-set statistical parameters. The results of this trial also demonstrated that nCRT and LE do not cause significant alterations in anorectal function and overall QOL measured one year after surgery, compared to baseline. Furthermore, half of the clinically staged T2N0 patients treated with nCRT and LE had pCR, and only one in 76 had a positive resection margin.

The changes in nCRT introduced in response to the unexpectedly high toxicity observed with the original nCRT regimen resulted in a reduction in the pCR and 3-year DFS rates. The results of recent phase 3 trials indicate that adding oxaliplatin to a fluoropyrimidine as a radiosensitizer in patients with rectal cancer increases toxicity without enhancing tumour response, compared to fluoropyrimidine alone.^[@R27]-[@R29]^ Based on this information, discontinuing oxaliplatin altogether may have been more effective in preventing toxicity, without affecting tumour response, than reducing the dose of capecitabine and radiation.

A transabdominal rectal resection is the recommended treatment for patients with T2N0 rectal cancer, and TME is the gold standard against which other surgical procedures should be compared.^[@R1]^ The 3-year DFS and OS in this trial are within the range of the rates reported for Stage I tumours treated with either laparoscopic or open TME in the recently published COLOR II trial.^[@R30]^ However, the COLOR II trial did not stratify the results of patients with Stage I disease by T categories. Retrospective case series and a cohort study from the National Cancer Database have reported 5-year LR rates ranging from 6% to 15% for T2N0 rectal cancers treated with transabdominal resection alone,^[@R12],\ [@R13],\ [@R31]^ higher than the 4% LR rate in this study. Recent population-based analysis from the NCDB and the Surveillance, Epidemiology and End Results (SEER) database have reported 5-year OS rates close to 76% for patients with T2N0 rectal cancer treated with transabdominal resection alone, lower than the estimated 5-year overall survival observed in this trial. However, comparisons between this trial and prospective studies or retrospective series of patients treated with transabdominal rectal resection are limited by patient selection bias. Patients in the Z6041 trial had tumours located within 8 cm of the anal verge, while patients in the TME series had tumours located anywhere in the rectum. As cancers located in the lower third of the rectum pose a higher risk of LR than cancers in the mid and upper rectum, a higher risk of recurrence should be expected in the Z6041 trial. On the other hand, the Z6041 trial was limited to tumours smaller than 4 cm in diameter, a selection criterion not applied in the transabdominal rectal resection series. In addition, results for the Z6041 trial are reported by clinical stage, whereas results in the transabdominal resection series were reported by pathological stage. Both ERUS and EC-MRI are known to overstage or understage some tumours.^[@R32],\ [@R33]^ It is likely that some of the ypT0, ypTis or ypT1 tumours in this trial may have been initially overstaged as T2 by ERUS. Conversely, the ypT3 tumours in this trial may represent either tumour progression during nCRT, or understaging by ERUS. Finally, LR tends to occur later in patients treated with nCRT and surgery, compared to those treated with surgery alone.^[@R15]^ In our series all patients received neoadjuvant radiation, compared to 59% in the COLOR II trial. Therefore, more patients in the Z6041 trial are likely to develop tumour relapse on longer follow-up.

Proving equivalence in oncologic efficacy between nCRT plus LE and TME for treatment of early rectal cancer would require a well-designed prospective, randomized trial. Given the relatively good prognosis of stage I rectal cancer, the required sample size will be large. In addition, patients' acceptance of randomization between LE and TME is questionable. Therefore, completion of such a study would be challenging. Lezoche, et al. reported the results of a prospective single-institution trial comparing nCRT and LE and transrectal partial mesorectal excision to nCRT and laparoscopic TME in patients with ultrasound-staged T2N0M0 rectal cancers, smaller than 3 cm in diameter, located within 6 cm of the anal verge, with well or moderately differentiated histology.^[@R19]^ After five years of follow-up, 8% of patients in the LE group and 6% in the TME group have developed LR, rates not very different than in this trial. Although underpowered to prove equivalence between nCRT plus LE and nCRT plus TME in uT2uN0 rectal cancer, Lezoche's study also suggests that nCRT plus LE may be an alternative to TME for patients with distal rectal cancer seeking organ-preserving treatment to avoid a permanent colostomy.

The justification for CRT and LE as an alternative to TME in patients with early-stage rectal cancer is the possibility of achieving equivalent oncologic results while preserving QOL. The baseline FISI total score in our patients was equivalent to those reported in patients with low rectal cancer enrolled in a prospective trial comparing functional outcomes after TME and different types of colorectal anastomosis. However, while in this study the FISI score remained essentially unaltered one year after CRT and LE, patients treated with TME had a significant deterioration in the FISI score at that time point, independent of the type of anastomosis.^[@R34]^ In this study the FACT-C overall score and the CCS subscale remained unchanged one year after surgery, compared to baseline. These findings are consistent with the recently published results of the NSABP R04^[@R35]^ trial that also reported no significant differences in the FACT-C scores (baseline vs. 1 year after surgery) in rectal cancer patients treated with nCRT and TME. The study has several important limitations. This is a single arm phase II trial, and the possibility of selecting fitter patients for nCRT and LE cannot be excluded. The sample size is relatively small. The follow-up is still short and, while most recurrences tend to arise in the first three years after treatment, nCRT delays the appearance of LR and it is possible that more patients may develop recurrence in the future. Finally, not all patients completed the 1-year FISI and FACT-C questionnaires, either because they passed away, developed recurrence, or simply did not return them. Therefore, our study may underestimate the real impact of nCRT and LE on ARF and QOL.

In conclusion, this study shows that nearly half of patients with clinically-staged T2N0 distal rectal cancer can achieve a pCR in response to nCRT. Rates of recurrence and survival are similar to patients with stage I tumours treated with TME. The majority of patients treated with nCRT and LE preserve the rectum with minimal deterioration in ARF and QOL up to one year after LE. While follow-up is still short, this study suggests that nCRT followed by LE may be an alternative to transabdominal rectal resection for carefully selected patients with T2N0 distal rectal cancer.

Supplementary Material {#SM}
======================

###### 

**Supplemental Figure 1.** Disease-free survival curves for the intention-to-treat group (A) and the per-protocol group (B) according to the dose group (OD= Original Dose; RD=Reduced Dose).

###### 

**Supplemental Figure 2.** Disease-free survival (A) and overall survival (B) curves for patients according to the type of surgery (TEM= Transanal Endoscopic Microsurgery; TAE= Transanal Excision).
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Disease-free survival curves for the intention-to-treat group (A) and the per-protocol group (B)
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###### 

Overall survival curves for the intention-to-treat group (A) and the per-protocol group (B)
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###### 

Baseline patient demographics and disease characteristics for all 79 patients accrued.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Demographic or\                                                             Original dose group\   Revised dose group\   Overall\      p-value
  Disease Characteristic                                                      (n = 53)               (n = 26)              (n = 79)      
  --------------------------------------------------------------------------- ---------------------- --------------------- ------------- ---------------------------------------
  **Age**, years[\*](#TFN5){ref-type="table-fn"}                              62 (30-80)             63 (45-83)            62 (30-83)    0.6954[2](#TFN2){ref-type="table-fn"}

                                                                                                                                         

  **Gender**                                                                                                                             

   Male                                                                       33 (62%)               20 (77%)              53 (67%)      0.1926[1](#TFN1){ref-type="table-fn"}

   Female                                                                     20 (38%)               6 (23%)               26 (33%)      

                                                                                                                                         

  **Race**                                                                                                                               0.7271[1](#TFN1){ref-type="table-fn"}

  White                                                                       47 (88.7%)             25 (96.2%)            72 (91.1%)    

  African Am.                                                                 2 (3.8%)               0 (0.0%)              2 (2.5%)      

  Nat. Hawaiian or Pac Isl.                                                   1 (1.9%)               0 (0.0%)              1 (1.3%)      

  Asian                                                                       1 (1.9%)               1 (3.8%)              2 (2.5%)      

  Am Indian or Alaska Nat.                                                    1 (1.9%)               0 (0.0%)              1 (1.3%)      

  Unknown                                                                     1 (1.9%)               0 (0.0%)              1 (1.3%)      

                                                                                                                                         

  **ECOG/Zubrod Performance Status**                                                                                                     0.4189[1](#TFN1){ref-type="table-fn"}

  0                                                                           47 (88.7%)             20 (76.9%)            67 (84.8%)    

  1                                                                           5 (9.4%)               5 (19.2%)             10 (12.6%)    

  2                                                                           1 (1.9%)               0 (0.0%)              1 (1.3%)      

  Missing                                                                     0                      1 (3.9%)              1 (1.3)       

                                                                                                                                         

  **Tumor Size**, cm [ψ](#TFN4){ref-type="table-fn"}                          2.8 ± 0.8              2.9± 0.7              2.8 ± 0.8     0.7242[3](#TFN3){ref-type="table-fn"}

                                                                                                                                         

  **Tumor Location**                                                                                                                     

   Anterior                                                                   11 (20.8%)             4 (15.4%)             15 (19.0%)    0.2213[1](#TFN1){ref-type="table-fn"}

   Posterior                                                                  29 (54.7%)             10 (38.5%)            39 (49.4%)    

   Left Lateral                                                               10 (18.9%)             7 (26.9%)             17 (21.5%)    

   Right Lateral                                                              3 (5.6%)               4 (15.4%)             7 (8.8%)      

   Missing                                                                    0                      1 (3.8)               1 (1.3%)      

                                                                                                                                         

  **Distance from Anal Verge**, (distal) cm [ψ](#TFN4){ref-type="table-fn"}   4.88 ± 1.91            5.30 ± 2.05           5.02 ± 1.95   0.2607[3](#TFN3){ref-type="table-fn"}
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Fisher's Exact Test

Equal Variance T-Test

Wilcoxon Rank Sum

Mean ± SD

Mean (Range)

###### 

Adverse events during neoadjuvant chemoradiotherapy for all 79 patients accrued.

  -----------------------------------------------------------------------------------------------------------------------------------
  Adverse Event Category     Original Dose\   Revised Dose\   Overall\                                                       
                             (n = 53)         (n = 26)        (n = 79)                                                       
  -------------------------- ---------------- --------------- ---------- ---------- --------- -------- ---------- ---------- --------
  **Gastrointestinal**       4 (8%)           18 (34%)        0          18 (69%)   5 (19%)   0        22 (28%)   23 (29%)   0

  **Pain**                   2 (4%)           9 (17%)         1 (2%)     16 (62%)   2 (8%)    0        18 (23%)   11 (14%)   1 (1%)

  **Dermatological**         2 (4%)           7 (13%)         0          7 (27%)    2 (8%)    0        9 (11%)    9 (11%)    0

  **Hematological**          1 (2%)           4 (8%)          1 (2%)     11 (42%)   6 (23%)   1 (4%)   12 (15%)   10 (13%)   (3%)

  **Infectious/Febrile**\    0                3 (6%)          1 (2%)     2 (8%)     0         0        2 (3%)     3 (4%)     1 (1%)
    **Neutropenia**                                                                                                          

  **Constitutional**\        5 (9%)           3 (6%)          0          17 (65%)   1 (4%)    0        22 (28%)   4 (5%)     0
    **Symptoms**                                                                                                             

  **Metabolic/Laboratory**   1 (2%)           2 (4%)          1 (2%)     9 (35%)    2 (8%)    1 (4%)   10 (13%)   4 (5%)     2 (3%)

  **Cardiovascular**         0                2 (4%)          1 (2%)     6 (23%)    0         0        6 (8%)     2 (3%)     1 (1%)

  **Hemorrhage**             0                1 (2%)          1 (2%)     4 (15%)    1 (4%)    0        4 (5%)     2 (3%)     1 (1%)

  **Lymphatic**              0                1 (2%)          0          2 (8%)     0         0        2 (3%)     1 (1%)     0

  **Neurological**           3 (6%)           1 (2%)          0          8 (31%)    0         0        11 (14%)   1 (1%)     0

  **Coagulation**            0                0               0          1 (4%)     1 (4%)    0        1 (1%)     1 (1%)     0

  **Musculoskeletal**        1 (2%)           0               0          0          1 (4%)    0        1 (1%)     1 (1%)     0

  **Renal/Genitourinary**    1 (2%)           0               0          12 (46%)   0         0        13 (16%)   0          0

  **Hepatic**                0                0               0          8 (31%)    0         0        8 (10%)    0          0
  -----------------------------------------------------------------------------------------------------------------------------------

###### 

Number of patients with adverse events during neoadjuvant chemoradiotherapy for all 79 patients accrued.

  ------------------------------------------------------------------------------------------------------------------------------------------------
  Adverse Event Category      Original Dose\   Revised Dose\   Overall\                                                                
                              (n = 53)         (n = 26)        (n = 79)                                                                
  --------------------------- ---------------- --------------- ----------- ----------- ----------- ----------- ----------- ----------- -----------
  **Gastrointestinal**        31 (58.5)        12 (22.6)       10 (18.9)   3 (11.5)    2 (7.7)     21 (80.8)   34 (43.0)   14 (17.7)   31 (39.2)

  **Pain**                    42 (79.2)        9 (17.0)        2 (3.8)     8 (30.8)    6 (23.1)    12 (46.2)   50 (63.3)   15 (19.0)   14 (17.7)

  **Dermatological**          44 (83.0)        8 (15.1)        1 (1.9)     17 (65.4)   5 (19.2)    4 (15.4)    61 (77.2)   13 (16.5)   5 (6.3)

  **Hematological**           48 (90.6)        4 (7.5)         1 (1.9)     9 (34.6)    3 (11.5)    14 (53.9)   57 (72.1)   7 (8.9)     15 (19.0)

  **Infectious/Febrile**\     50 (94.3)        3 (5.7)         0           24 (92.3)   2 (7.7)     0           74 (93.7)   5 (6.3)     0
    **Neutropenia**                                                                                                                    

  **Constitutional**\         45 (84.9)        7 (13.2)        1 (1.9)     8 (30.8)    9 (34.6)    9 (34.6)    53 (67.1)   16 (20.3)   10 (12.7)
    **Symptoms**                                                                                                                       

  **Metabolic/Laboratory**    52 (98.1)        1 (1.9)         0           15 (57.7)   3 (11.5)    8 (30.8)    65 (82.3)   4 (5.1)     10 (12.7)

  **Cardiovascular**          51 (96.2)        2 (3.8)         0           20 (76.9)   6 (23.1)    0           71 (89.9)   8 (10.1)    0

  **Hemorrhage**              52 (98.1)        1 (1.9)         0           21 (80.8)   5 (19.2)    0           73 (92.4)   6 (7.6)     0

  **Lymphatic**               52 (98.1)        1 (1.9)         0           24 (92.3)   2 (7.7)     0           76 (96.2)   3 (3.8)     0

  **Neurological**            49 (92.4)        3 (5.7)         1 (1.9)     18 (69.2)   2 (7.7)     6 (23.1)    67 (84.8)   5 (6.3)     7 (8.9)

  **Coagulation**             53 (100)         0               0           24 (92.3)   2 (7.7)     0           77 (97.5)   2 (2.5)     0

  **Musculoskeletal**         52 (98.1)        1 (1.9)         0           25 (96.2)   1 (3.8)     0           77 (97.5)   2 (2.5)     0

  **Renal/Genitourinary**     52 (98.1)        1 (1.9)         0           14 (53.8)   10 (38.5)   2 (7.7)     66 (83.5)   11 (13.9)   2 (2.5)

  **Hepatic**                 53 (100)         0               0           18 (69.2)   4 (15.4)    4 (15.4)    71 (89.9)   4 (5.1)     4 (5.1)

  **Ocular/Visual**           53 (100)         0               0           22 (92.3)   3 (11.5)    1 (3.8)     75 (94.9)   3 (3.8)     1 (1.3)

  **Pulmonary**               51 (96.2)        2 (3.8)         0           25 (96.2)   1 (3.8)     0           76 (96.2)   3 (3.8)     0

  **Sexual /Reproductive**\   53 (100)         0               0           23 (88.5)   2 (7.7)     1 (3.8)     66 (83.5)   11 (13.9)   2 (2.5)
    **Function**                                                                                                                       

  **Syndromes**               53 (100)         0               0           25 (96.2)   1 (3.8)     0           78 (98.7)   1 (1.3)     0

  **Endocrine**               53 (100)         0               0           25 (96.2)   1 (3.8)     0           78 (98.7)   1 (1.3)     0
  ------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Surgery-related adverse events for all eligible patients who underwent surgery (n = 77).

  --------------------------------------------------------------------------------------------------------------------------
  Adverse Event Category    Original Dose\   Revised Dose\   Overall\                                               
                            (n = 52)         (n = 25)        (n = 77)                                               
  ------------------------- ---------------- --------------- ---------- ---------- -------- --- ---------- -------- --------
  **Hematological**         0                1 (2%)          0          0          1 (4%)   0   0          2 (3%)   0

  **Hemorrhage**            1 (2%)           1 (2%)          1 (2%)     4          1 (4%)   0   5 (6%)     2 (3%)   1 (1%)

  **Infectious/Febrile**\   3 (6%)           1 (2%)          0          1 (4%)     1 (4%)   0   4 (5%)     2 (3%)   0
    **Neutropenia**                                                                                                 

  **Pain**                  13 (25%)         5 (10%)         0          7 (28%)    1 (4%)   0   20 (26%)   6 (8%)   0

  **Gastrointestinal**      8 (15%)          3 (6%)          0          11 (44%)   0        0   19 (25%)   3 (4%)   0

  **Neurological**          0                0               0          2 (8%)     1 (4%)   0   2 (3%)     1 (1%)   0
  --------------------------------------------------------------------------------------------------------------------------

###### 

Characteristics of patients developing tumour recurrence

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Location   Tumor\                                Distance[2](#TFN7){ref-type="table-fn"}   Treatment\   ypT    Time to\                                    Additional\                                Follow-\                             Survival status
             Size[1](#TFN6){ref-type="table-fn"}                                             dose                recurrence[3](#TFN8){ref-type="table-fn"}   Treatment[4](#TFN9){ref-type="table-fn"}   up[5](#TFN10){ref-type="table-fn"}   
  ---------- ------------------------------------- ----------------------------------------- ------------ ------ ------------------------------------------- ------------------------------------------ ------------------------------------ --------------------
  Local      0.3                                   3.0                                       OD           ypT1   34                                          APR                                        42                                   Alive with disease

  Local      3.0                                   5.0                                       OD           ypT3   6                                           Chemotherapy                               58                                   Alive with disease

  Local      3.4                                   8.0                                       RD           ypT2   6                                           APR                                        48                                   Alive, NED

  Liver      2.0                                   2.0                                       RD           ypT1   14                                          Liver resection                            55                                   Alive, NED

  Lung       2.0                                   3.5                                       OD           ypT2   26                                          Lung Resection                             60                                   Alive, NED

  Lung       2.9                                   6.0                                       RD           ypT0   17                                          Lung resection                             46                                   Alive, NED

  Lung       3.0                                   6.0                                       OD           ypT0   33                                          Chemotherapy                               55                                   Alive with disease

  Uterus     3.0                                   3.0                                       OD           ypT0   45                                          Hysterectomy                               63                                   Died from disease
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Tumour size at diagnosis measured in cm

Distance from anal verge measured in cm

Time to recurrence from local excision, months

Treatment for recurring disease

Length of follow-up after local excision, months

###### 

Baseline and 12 month FISI and FACT-C scores.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                Baseline [ψ](#TFN12){ref-type="table-fn"}\   12 Months [ψ](#TFN12){ref-type="table-fn"}\   Mean Absolute\    p-value
                                (n = 72)                                     (n = 66)                                      Difference (SD)   
  ----------------------------- -------------------------------------------- --------------------------------------------- ----------------- ----------------------------------------
  **FISI**                                                                                                                                   

   Overall                      26.2 (16.7)                                  27.8 (17.1)                                   1.5 (19.4)        0.7382[1](#TFN11){ref-type="table-fn"}

   Gas                          7.8 (5.0)                                    7.9 (4.5)                                     −0.4 (5.4)        0.7322[1](#TFN11){ref-type="table-fn"}

   Mucus                        3.0 (4.1)                                    3.3 (4.1)                                     0.1 (5)           0.5831[1](#TFN11){ref-type="table-fn"}

   Liquid Stool                 6.2 (6.9)                                    7.2 (6.4)                                     1.2 (6.9)         0.3876[1](#TFN11){ref-type="table-fn"}

   Solid Stool                  9.5 (7.9)                                    9.8 (7.5)                                     0.6 (9.9)         0.7023[1](#TFN11){ref-type="table-fn"}

                                                                                                                                             

  **FACT-C**                                                                                                                                 

   Overall                      112.2 (13.5)                                 109.3 (18.9)                                  −2.17 (16.5)      0.6843[1](#TFN11){ref-type="table-fn"}

   Physical WB                  25.17 (3.8)                                  23.85 (4.7)                                   −1.15 (3.2)       0.0363[1](#TFN11){ref-type="table-fn"}

   Social/Family WB             25.26 (3.5)                                  23.74 (5.2)                                   −1.5 (5.3)        0.0940[1](#TFN11){ref-type="table-fn"}

   Emotional WB                 18.62 (3.9)                                  20.09 (3.5)                                   1.7 (3.7)         0.0285[1](#TFN11){ref-type="table-fn"}

   Functional WB                22.5 (4.7)                                   22.26 (5.7)                                   −0.1 (5.4)        0.8332[1](#TFN11){ref-type="table-fn"}

   Colorectal Cancer Subscale   20.66 (3.1)                                  19.63 (3.8)                                   −0.75 (4.2)       0.1032[1](#TFN11){ref-type="table-fn"}
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Wilcoxon Signed Rank Test

Mean (SD)

###### RESEARCH IN CONTEXT

Evidence before this study {#S15}
==========================

Local excision of stage I rectal cancer is appealing because it could potentially cure the cancer while preserving the organ. However, local excision (LE) alone for T2N0 rectal cancer patients is associated with higher rates of local recurrence (LR), and inferior survival, compared to a transabdominal resection. The use of neoadjuvant chemoradiotherapy (nCRT) to reduce the risk of LR in patients with early-stage rectal cancer treated with LE is an extrapolation of results obtained for patients with advanced rectal cancer treated with transabdominal rectal resection. A number of retrospective, single-institution case series have reported low rates of LR in selected patients with T2-3N0 rectal cancer receiving nCRT before LE. However, these studies are limited by small sample sizes, variable clinical staging criteria and imaging modalities, heterogeneous tumour characteristics, and varying CRT regimens. In addition, information on functional outcomes and quality of life (QOL) is lacking.

Added value of this study {#S16}
=========================

This multi-institutional prospective trial shows that nCRT results in a high rate of tumour response, and low rate of LR, in a defined population of patients with early-stage distal rectal cancer. It also indicates that most patients with distal T2N0 rectal cancer treated with nCRT and LE can preserve the rectum while achieving a survival equivalent to patients treated with transabdominal rectal resection. Finally, our study suggests that nCRT followed by LE has minimal impact on anorectal function and QOL.

Implications of all the available evidence {#S17}
==========================================

The results of this study suggest that nCRT followed by LE may be an alternative to transabdominal rectal resection for patients with early-stage distal rectal cancer who are unfit for major surgery, or seek preservation of the rectum.
